News

UNC's 340B Pharmacy Receives Accreditation as a Specialty Pharmacy from URAC

UNC's 340B pharmacy's accreditation by URAC became effective February 1, 2016. URAC's mission is to promote continuous improvement in the quality and efficiency of health care management through processes of accreditation, education, and measurement.

UNC's 340B Pharmacy Receives Accreditation as a Specialty Pharmacy from URAC - Read More…

ISTH Releases New Clinical Core Curriculum on Thrombosis and Hemostasis

In a press release dated January 19, 2016, the International Society on Thrombosis and Haemostasis (ISTH) announced its new international clinical Core Curriculum on thrombosis and hemostasis, the first framework of its kind to define the minimum standards for a medical doctor to attain a level of proficiency to enable them to practice independently as specialists in the field.

ISTH Releases New Clinical Core Curriculum on Thrombosis and Hemostasis - Read More…

Nigel Key, M.D. featured in WebMD article about new treatments for hemophilia

Nigel Key, M.D., Director of the UNC Hemophilia and Thrombosis Center, is extensively quoted in the January 12, 2016 WebMD article "Hemophilia: New Treatments for an Old Disease," by Sonya Collins.

Nigel Key, M.D. featured in WebMD article about new treatments for hemophilia - Read More…

Brenda Nielsen, RN, Named to Advisory Council on Rare Disease

Brenda Nielsen, RN, nurse in the UNC Comprehensive Hemophilia Diagnostic and Treatment Center, will serve a three-year term on this council beginning December 1, 2015 through November 30, 2018.

Brenda Nielsen, RN, Named to Advisory Council on Rare Disease - Read More…

UNC team walks to raise money for 2015 Hemophilia Walk

UNC team walks to raise money for 2015 Hemophilia Walk

On October 17, The UNC TarHealers walk team raised $5,160 for the Raleigh Hemophilia Walk, which benefits Hemophilia of North Carolina and the National Hemophilia Foundation.

UNC team walks to raise money for 2015 Hemophilia Walk - Read More…

Nigel Key, M.D. Gives The Dr. William Bell Lecture in Hematology at Johns Hopkins University

Dr. Key's lecture, which was delivered on Monday, October 19, 2015, was entitled "Thrombosis in Hemolytic Anemias: What are the Common Themes?"

Nigel Key, M.D. Gives The Dr. William Bell Lecture in Hematology at Johns Hopkins University - Read More…

Alice Ma Delivers Whitehead Lecture

Alice Ma, MD, associate professor, department of medicine, division of hematology-oncology, delivered this year's Whitehead Lecture on August 19. The themes of Ma’s lecture closely followed its title: “Endurance, Obstacles, Perseverance and Joy: My Transformation from the World’s Crummiest Medical Student to Faculty at the World’s Best Medical School.”

Alice Ma Delivers Whitehead Lecture - Read More…

8th Symposium on Hemostasis to be held in Chapel Hill May 12-14, 2016

The 8th Symposium on Hemostasis: Translational and Basic Science Discoveries will be held May 12-24, 2016 in Chapel Hill, North Carolina.

8th Symposium on Hemostasis to be held in Chapel Hill May 12-14, 2016 - Read More…

New gene therapy for hemophilia shows potential as safe treatment

Research showed that bleeding events were drastically decreased in animals with hemophilia B. Using a viral vector to swap out faulty genes proved safe and could be used for the more common hemophilia A.

New gene therapy for hemophilia shows potential as safe treatment - Read More…

Nigel Key to deliver MacFarlane Biggs Lecture at British Society for Haemostasis and Thrombosis Annual Scientific Meeting in April

Nigel Key, MD, Director of the UNC Hemophilia and Thrombosis Center, has been invited to deliver a state-of-the-art lecture at the British Society for Haematology Annual Scientific Meeting on April 20, 2015.

Nigel Key to deliver MacFarlane Biggs Lecture at British Society for Haemostasis and Thrombosis Annual Scientific Meeting in April - Read More…

UNC's Stephan Moll, MD comments on FDA approval of edoxaban (Savaysa) for atrial fibrillation, DVT, and PE

On Friday, January 9, the Food and Drug Administration approved edoxaban (Savaysa) as the fourth new oral anticoagulant (NOAC), giving it an indication in nonvalvular atrial fibrillation for renally impaired patients and in treating deep vein thrombosis and pulmonary embolism.

UNC's Stephan Moll, MD comments on FDA approval of edoxaban (Savaysa) for atrial fibrillation, DVT, and PE - Read More…

Letter by UNC hematology team published in "Haemophilia"

"Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency," a letter to the editor of the journal "Haemophilia" by UNC-Chapel Hill hematologists Tyler Buckner, MD, Brenda Nielsen, MSN, Nigel Key, MD, and Alice Ma, MD, was published online on December 4, 2014.

Letter by UNC hematology team published in "Haemophilia" - Read More…

Gene therapy provides safe, long-term relief for patients with severe hemophilia B

Gene therapy developed at St. Jude Children's Research Hospital, University College London (UCL) and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers reported. The results appear in the November 20 edition of The New England Journal of Medicine.

Gene therapy provides safe, long-term relief for patients with severe hemophilia B - Read More…

FDA approves new treatment for rare form of hemophilia

On October 23, 2014, the U.S. Food and Drug Administration approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVIII] deficiency).

FDA approves new treatment for rare form of hemophilia - Read More…

FDA approves Baxter's RIXUBIS for treatment of children with hemophilia B

On September 12, 2014, the United States Food and Drug Administration (FDA) approved Baxter International Inc.'s RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B.

FDA approves Baxter's RIXUBIS for treatment of children with hemophilia B - Read More…

Nigel Key assumes chairmanship of the ISTH Council

Nigel Key, MD, Director of the UNC Hemophilia and Thrombosis Center, transitioned from the position of Chairman-Elect of the International Society on Thrombosis and Haemostasis Council to the role of Chairman at the ISTH Council meeting in Milwaukee June 23-26, 2014. Dr. Key's term will extend for two years.

Nigel Key assumes chairmanship of the ISTH Council - Read More…

U.S. FDA approves Biogen's hemophilia A drug Eloctate

On Friday, June 6, 2014, the U.S. Food and Drug Administration approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have hemophilia A. Eloctate is the first hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

U.S. FDA approves Biogen's hemophilia A drug Eloctate - Read More…

New report released on CDC's Universal Data Collection program

The CDC established a national public health surveillance project called the Universal Data Collection (UDC) system, which was carried out by the CDC and federally funded hemophilia treatment centers (HTCs) from 1998 through 2011.

New report released on CDC's Universal Data Collection program - Read More…

U.S. FDA approves Biogen's hemophilia B drug Alprolix

Biogen Idec, Inc. has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration announced on Friday, March 28, 2014.

U.S. FDA approves Biogen's hemophilia B drug Alprolix - Read More…